코로나19 백신 개발사 큐어백 "임상시험서 면역반응"<br /><br />German biotech company, CureVac, recorded an immune reaction from a potential vaccine in a clinical trial on Monday.<br />According to local media outlets, its CEO Franz-Werner Haas was encouraged by the interim results from early trials.<br />This company is using the so-called messenger RNA approach, the same as Moderna, and began mass testing on people in July.<br />Their dose sparked increases in virus-neutralizing antibodies and early indications of T-cell activation.<br />They are planning to go through the last phase of the trial with 30-thousand applicants before the end of this year.<br /><br />
